The mental health question around GLP-1 drugs has mostly been a worry story: does semaglutide increase suicide risk, is there a link to depression, what happened to those European regulator warnings. So it’s worth sitting with a study that points the other way, and it comes from a team with Australian leadership.
Researchers led by Professor Mark Taylor from Griffith University’s School of Medicine and Dentistry analysed Swedish nationwide registry data covering nearly 15,000 people with bipolar disorder who were prescribed GLP-1 medications across a 15-year window. The paper, published in Acta Psychiatrica Scandinavica, found that periods when people were taking semaglutide were associated with significantly lower rates of psychiatric hospitalisation than periods when they weren’t.
What the Research Says
The key findings from the Griffith University release and the paper (‘Use of glucagon-like peptide 1 receptor agonists and the associated risk of hospitalisation in bipolar disorder, from a nationwide cohort, 2009-2024’, DOI: 10.1111/acps.70120):
- Semaglutide was associated with a 21% lower risk of psychiatric hospitalisation compared with periods off GLP-1 treatment
- The effect was not seen with liraglutide or dulaglutide - the association was specific to semaglutide, not the whole class
- The proposed mechanism is indirect: GLP-1 signalling may reduce neuroinflammation, cellular stress, and other biological processes that have been linked to bipolar disorder pathophysiology
The Swedish registry design here is the same self-controlled methodology that produces most of the interesting GLP-1 observational research: each person acts as their own comparison across treatment periods. That controls for a lot of confounding, which is why registry studies like this keep surfacing effects that targeted trials hadn’t looked for.
Why the Drug-Specific Signal Matters
The most interesting part of this study isn’t the 21% figure - it’s the split between drugs. If the effect were just “people losing weight feel better,” you’d expect it across the class. Finding it only with semaglutide points toward something pharmacological rather than psychological. Semaglutide crosses the blood-brain barrier more readily than some other GLP-1 compounds, and the paper suggests central GLP-1 signalling may play a role in mood stability.
This also fits a broader pattern in the 2026 literature. A separate Swedish-Karolinska-Griffith analysis published earlier this year found semaglutide use associated with 44% lower depression risk, 38% lower anxiety disorder rates, and 47% lower substance-use-related hospital care (ScienceDaily coverage of that March paper). Different cohorts, same direction of travel, and again with semaglutide at the centre.
The honest caveat, which Professor Taylor himself flags: this is observational. Registry associations show correlation across time periods within people, not causation, and confounding by indication is a live issue - people prescribed GLP-1s for diabetes or obesity in a bipolar cohort may differ from those who weren’t. Taylor has said the finding needs testing in a randomised controlled trial, which is the honest next step. Until then, this is hypothesis-generating, not practice-changing.
Context for the Australian Research Interest Community
Bipolar disorder affects roughly one in 200 people globally by WHO estimates, and it co-occurs with diabetes and obesity at well above chance rates - the shared metabolic and inflammatory pathways are an active research area. That overlap is exactly why GLP-1 compounds keep getting studied in psychiatric populations despite being designed for metabolic indications.
There’s also a data-quality angle worth noting for anyone following the grey market discussion here in Australia: this study used registry-linked prescription records, not self-reported use. The quality of the exposure data is what makes the analysis possible, and it’s a reminder of how much weaker the evidence base gets in grey-market contexts where nobody knows what compound, what dose, or what purity is actually in play. Our semaglutide overview covers the compound’s trial history in more detail.
The counter-narrative matters too: the psychiatric side-effect signal that prompted European regulators to add warnings in 2024 and 2025 has never fully disappeared from the pharmacovigilance data. This bipolar study doesn’t resolve that tension - it just adds a data point suggesting the net psychiatric effect may be more complicated than the warning labels imply. Randomised trials will be the arbiter.
If you want to argue about the mechanism or the methodology - and people absolutely will - the Grey Highway Telegram group is the place for it.
Sources
- Taylor M et al., ‘Use of glucagon-like peptide 1 receptor agonists and the associated risk of hospitalisation in bipolar disorder, from a nationwide cohort, 2009-2024’, Acta Psychiatrica Scandinavica, DOI: 10.1111/acps.70120
- Griffith University news release, August 24, 2026: Weight loss drugs may help with mental health
- SciMex release summary: Weight loss drugs may help with mental health
- ScienceDaily, March 2026: Weight loss drug Ozempic cuts depression, anxiety, and addiction risk
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.